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Abstract Advanced aging may contribute to impairment of
angiogenesis and development of vascular diseases. Telomerase
was shown to delay endothelial cell (EC) senescence. Therefore,
we determined the regulation of telomerase activity in EC.
Inhibition of phosphoinositol 3-kinase (PI3K) suppressed telo-
merase activity, whereas inhibitors directed against ERK1/2 or
protein kinase C had no effect. Dominant negative Akt
significantly reduced telomerase activity. Moreover, pro-athero-
genic stimuli such as oxidized low density lipoprotein led to an
inactivation of Akt and diminished telomerase activity. Thus, the
PI3K/Akt pathway plays an important role in the regulation of
telomerase activity. Pro-atherosclerotic factors impair telomer-
ase activity and thereby may promote EC aging. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
The integrity of endothelial cell (EC) function is compro-
mised by advancing age and its impairment contributes to
insu⁄cient angiogenesis and age-dependent development of
vascular diseases such as atherosclerosis [1^3]. At a cellular
level, aging leads to an irreversible state of cell cycle arrest
known as replicative senescence [4], which is mainly deter-
mined by telomere length [5]. Telomerase, a ribonucleoprotein
with reverse transcriptase activity, synthesizes telomeric re-
peats at the linear ends of eukaryotic chromosomes [5,6]. Us-
ing the 3P-OH group at the DNA terminus as a primer, the
catalytic component of telomerase, the telomerase reverse
transcriptase (TERT), copies repeatedly only a very restricted
region of the telomerase RNA component coding for the telo-
mere repeats. This repeated reverse transcription of the tem-
plate region can occur in a more or less processive manner,
depending on the cellular system [6].
Stable overexpression of telomerase prevents EC senescence
suggesting an important role for telomerase activity in the
extension of the life span of somatic cells [7]. Although the
molecular mechanisms involved in the tight regulation of
telomerase expression in somatic cells are largely unde¢ned,
evidence is accumulating that post-transcriptional modi¢ca-
tion of telomerase by phosphorylation processes importantly
modulates telomerase activity in a variety of cancer cells [8^
11]. Speci¢cally, it has been shown that the serine/threonine
kinase Akt can enhance telomerase activity in melanoma cells
[12]. Because Akt is a potent survival signaling kinase in EC
[13,14] and importantly contributes to endothelial function
[15], we investigated the potential involvement of Akt in the
regulation of TERT activity in ECs. In addition, since the
pro-atherosclerotic risk factor homocysteine has been shown
to accelerate EC senescence [16], we tested the hypothesis that
atherosclerotic risk factors might interfere with endothelial
telomerase activity.
2. Materials and methods
2.1. Cell culture
Human umbilical cord endothelial cells (HUVEC) were purchased
from Cell Systems/Clonetics (Solingen, Germany), and cultured in
endothelial basal medium (EBM) supplemented with hydrocortisone
(1 Wg/ml), bovine brain extract (3 Wg/ml), gentamicin (50 Wg/ml), am-
photericin B (50 Wg/ml), epidermal growth factor (10 Wg/ml) and 10%
fetal calf serum (FCS) until the third passage. COS-7 cells were cul-
tured in Dulbecco’s modi¢ed Eagle’s medium with 10% FCS and
2 mM L-glutamine.
2.2. Plasmids and transfection studies
Plasmids encoding the bovine Akt and the truncated dominant
negative Akt mutant were kindly donated by Dr. J. Downward [17]
and were subcloned into the pcDNA3.1(3)myc-his vector as described
[18]. Human TERT cDNA was a gift from Dr. R.A. Weinberg [19]
and was subcloned in the pcDNA3.1(3)myc-his vector. Clones with a
veri¢ed sequence were transfected in HUVEC (4.0U105 cells/6 cm
plate; 3 Wg plasmid DNA; 25 Wl Superfect) as described previously
[18]. Transient transfections of COS-7 cells were performed as previ-
ously outlined [20].
2.3. Western blot analysis
Cells were lysed as described [18]. Western blots were performed
with either anti-phospho Akt antibody (New England Biolabs,
Schwalbach, Germany), anti-myc antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) or anti-Akt antibody (New England Bio-
labs).
2.4. Telomeric repeat ampli¢cation protocol (TRAP) assay
A PCR^ELISA-based assay (Roche Molecular Biochemicals,
Mannheim, Germany) was used to measure the telomerase activity
as previously described [21]. The levels of telomerase activity were
within the linear range of the TRAP assay. For visualizing, the telo-
merase-synthesized DNA ladder was transferred to nylon membranes
and the Biotin Luminescent Detection Kit was subsequently applied
according to the manufacturer’s instructions (Roche Molecular Bio-
chemicals).
2.5. In vitro kinase assay
For phosphorylation of TERT by Akt kinase in vitro, myc-tagged
TERT and Akt were overexpressed in COS-7 cells and isolated by
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immunoprecipitation with an anti-myc antibody (Santa Cruz Biotech-
nology). In vitro Akt kinase assays were then carried out as described
[20]. The reactions were terminated by addition of sodium dodecyl
sulfate (SDS) loading dye and samples were subjected to 8% SDS^
PAGE and analyzed by a PhosphorImager or autoradiography.
2.6. Statistics
Data are expressed as mean þ S.E.M. from at least three indepen-
dent experiments. Statistical analysis was performed with ANOVA
followed by a modi¢ed LSD test (SPSS Software).
3. Results
3.1. Regulation of telomerase activity by protein kinases
HUVEC starved with serum-free medium for 18 h revealed
a 70% reduction of telomerase activity (Fig. 1A). To deter-
mine which protein kinase is responsible for the maintenance
of telomerase activity under serum-containing conditions, we
assayed the telomerase activity of HUVEC that were treated
with several protein kinase inhibitors against phosphoinositol
3-kinase (PI3K), mitogen-activated protein kinases ERK1/2
and protein kinase C (PKC). The PI3K inhibitor Ly294002
signi¢cantly reduced telomerase activity (Fig. 1B,C). The
treatment of cells with PD98059, an inhibitor of the ERK1/2
pathway, slightly a¡ected telomerase activity, whereas bisin-
dolylmaleimide I, an inhibitor highly speci¢c for PKC, did not
alter telomerase activity (Fig. 1D). Furthermore, incubation
of HUVEC with a combination of PD98059 and Ly294002
did not result in an additive decrease of TERT activity, in-
dicating a dominant PI3K-dependent signal transduction
pathway in altering telomerase activity (Fig. 1D).
3.2. Akt regulates telomerase activity in EC
Since Akt is an important downstream mediator of PI3K
signaling, HUVEC were transiently transfected with either
empty vector, myc epitope-tagged wild-type Akt, constitu-
tively active Akt or dominant negative Akt expression con-
structs in order to assess the direct in£uence of Akt on telo-
merase activity. As illustrated in Fig. 2, the expression of
dominant negative Akt resulted in a signi¢cant reduction of
telomerase activity, whereas expression of a constitutively ac-
tive Akt construct led to an enhancement of telomerase activ-
ity. These data indicate that Akt importantly contributes to
the regulation of telomerase activity in HUVEC.
3.3. Phosphorylation of TERT by Akt kinase
To determine the phosphorylation of TERT by Akt, myc
epitope-tagged Akt and the myc-tagged TERT construct were
overexpressed in COS-7 cells followed by immunoprecipita-
tion of the respective proteins. An in vitro kinase assay dem-
onstrates that TERT is phosphorylated in the presence of Akt
kinase (Fig. 3).
3.4. Pro-atherogenic stimuli inhibit telomerase activity
Pro-atherogenic stimuli were shown to accelerate EC sen-
escence [16]. Therefore, we investigated the e¡ect of tumor
necrosis factor K (TNFK), oxidized low density lipoprotein
(oxLDL) and H2O2 on telomerase activity. All stimuli signi¢-
cantly inhibited telomerase activity in ECs (Fig. 4A). Concen-
trations as low as 10 ng/ml TNFK were su⁄cient to signi¢-
cantly reduce telomerase activity (data not shown). The e¡ect
of oxLDL on telomerase activity was dose-dependent with a
maximal e⁄cacy at a concentration of 10 Wg/ml oxLDL (Fig.
4A, data not shown). Incubation of whole cell extract with
H2O2 or oxLDL in vitro did not a¡ect telomerase activity
(data not shown) indicating that inactivation of TERT is
not due to direct oxidation.
To address whether inactivation of the PI3K/Akt pathway
is involved in pro-atherogenic stimulus-induced telomerase in-
activation, HUVEC were treated with TNFK, oxLDL and
H2O2, and Akt activity was determined by Western blot anal-
ysis with an anti-phospho Akt antibody directed against ser-
ine residue 473 [13]. As illustrated in Fig. 4B, incubation with
oxLDL, TNFK or H2O2 resulted in dephosphorylation of
Akt. The direct involvement of an Akt kinase-mediated mech-
Fig. 1. Telomerase activity is dependent on phosphorylation processes. A: HUVEC were incubated in EBM containing 1% bovine serum albu-
min (BSA) for 18 h (without FCS) and telomerase activity was determined by the TRAP assay. Data are mean þ S.E.M., *P6 0.0001 versus
control, n = 10. B,C: HUVEC were incubated in EBM containing 1% BSA for 8 h, then EBM supplemented with growth factors and 10% FCS
was added. 10 WM Ly294002 was then added for 18 h and telomerase activity was quantitatively measured (B) and visualized as described in
Section 2 (C). EC lysate with heat-inactivated telomerase activity served as negative control. HeLa cell extracts were used as positive control.
Data are mean þ S.E.M., *P6 0.0005 versus control, n = 4. D: HUVEC were incubated as described for B with PD98059 (PD; 10 WM),
Ly294002 (Ly; 10 WM) or bisindolylmaleimide (Bis I; 10 nM). Data are mean þ S.E.M., *P6 0.05 versus control, n = 4; **P6 0.005 versus
+PD, n = 4.
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anism on telomerase inactivation by pro-atherogenic stimuli
was further demonstrated with TNFK. For this purpose, HU-
VEC were transiently transfected with either empty vector or
constitutively active myc-tagged Akt expression constructs.
Following 6 h transfection, cells were treated with TNFK
for 18 h and telomerase activity was monitored by a TRAP
assay. Fig. 4C demonstrates that telomerase activity in cells
expressing active Akt was only slightly reduced by TNFK to
basal levels. In contrast, cells that were transfected with empty
vector revealed a dramatic decrease in telomerase activity in
the presence of TNFK (Fig. 4C). These data suggest that
TNFK-triggered reduction of telomerase activity involved in-
activation of the PI3K/Akt signal transduction pathway.
Since Akt kinase is known to activate the endothelial nitric
oxide (NO) synthase [18] and NO prevents age-related down-
regulation of telomerase activity [21], we tested the e¡ect
of the NO synthase inhibitor NG-monomethyl-L-arginine
(LNMMA). As illustrated in Fig. 4A, LNMMA did not a¡ect
telomerase activity.
4. Discussion
The data of the present study indicate an important regu-
latory role of the cell survival kinase Akt for the maintenance
of telomerase activity by possible phosphorylation of its cata-
lytic subunit TERT. Pro-in£ammatory and pro-atheroscler-
otic factors such as TNFK, oxLDL or H2O2 reduce telomer-
ase activity in human ECs, and might thereby contribute to
accelerated senescence of ECs.
Fig. 2. Direct in£uence of Akt on telomerase activity. HUVEC were transiently transfected with either empty vector, wild-type Akt, dominant
negative Akt or constitutively active Akt constructs. Following transfection, cells were ¢rst incubated with EBM containing 1% BSA for 6 h
and then with EBM supplemented with growth factors and 10% FCS for an additional 18 h. Cells were lysed and applied to the TRAP assay,
quanti¢ed (A) and visualized (B) as described in Section 2. Data are mean þ S.E.M., *P6 0.005 versus wild-type Akt, nv6. C: Expression of
the various Akt constructs was veri¢ed by Western blot analysis using an anti-myc antibody.
C
Fig. 3. Phosphorylation of TERT by Akt in vitro. A: Myc-tagged
full-length TERT was transiently transfected into COS-7 cells and
TERT was isolated via immunoprecipitation with an anti-myc anti-
body. The kinase assay was carried out as described Section 2.
B: Histone H1 was used as a positive control for Akt activity.
C: Western blot analysis with anti-myc antibody con¢rms Akt and
TERT expression in COS-7 cells.
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The reduction of TERT activity in ECs by inhibition of the
PI3K/Akt pathway extends the results of a recent study in a
human melanoma cell line, which demonstrated that Akt en-
hances telomerase activity through phosphorylation of TERT
[12]. Indeed, the present study disclosed a direct phosphory-
lation of full-length TERT by Akt in vitro. In contrast, PKCK
and the mitogen-activated protein kinase ERK2 did not phos-
phorylate TERT (data not shown), in accordance with the
lack of pharmacological inhibition of ERK1/2 or PKC to
signi¢cantly alter telomerase activity in HUVEC. Thus, the
PI3K/Akt pathway seems to play a predominant role in telo-
merase activation within ECs.
Beside the direct phosphorylation of TERT, Akt might also
act by increasing the activity of the endothelial NO synthase
[18,22]. This has to be taken into account because we recently
demonstrated that long-term NO addition can prevent age-
associated down-regulation of EC TERT activity [21]. How-
ever, a sole e¡ect of Akt via NO was ruled out by the ¢nding
that acute inhibition of the NO synthase by LNMMA did not
impair EC TERT activity. Taken together, although the over-
all organization of telomerase activity is still enigmatic, our
data indicate an important regulatory role of Akt in the main-
tenance and enhancement of telomerase activity in ECs with
Akt acting directly in an acute fashion most likely via phos-
phorylation of the regulatory subunit of the telomerase,
whereas NO has additional long-term e¡ects by an unknown
mechanism.
The data of the present study demonstrated that pro-athero-
sclerotic factors impair telomerase activity. Mechanistically,
the inhibition of telomerase activity seems to be mediated
by reduction of the Akt phosphorylation resulting in deacti-
vation of the kinase. The reduction of Akt phosphorylation
by TNFK and oxLDL is in accordance with previous ¢ndings
in ECs [23,24] and might be due to activation of the ceramide/
sphingomyelinase pathway, which is known to promote Akt
dephosphorylation [23,25]. However, other studies have re-
ported that TNFK can also stimulate Akt [26,27]. Similarly,
H2O2 was shown to augment Akt phosphorylation in vascular
smooth muscle cells [28]. One may speculate that the discrep-
ancies of these studies might be due to cell type speci¢cities.
Although the mechanism by which Akt phosphorylation is
reduced by TNFK, oxLDL and H2O2 remains to be eluci-
dated, a causal role for Akt deactivation in the reduction of
telomerase activity is evidenced by the ¢nding that overexpres-
sion of a constitutively active Akt construct prevents TNFK-
induced telomerase inactivation.
In conclusion, the prevention of telomerase inactivation by
pro-atherosclerotic factors by Akt might be of substantial
Fig. 4. Pro-atherogenic stimuli signi¢cantly a¡ect telomerase activity. A: HUVEC were incubated with a series of pro-atherogenic stimuli
(oxLDL (10 Wg/ml), TNFK (100 ng/ml), H2O2 (200 WM), or LNMMA (1 mM)) for 18 h. B: oxLDL, TNFK and H2O2 induce dephosphoryla-
tion of Akt at serine residue 473. HUVEC were treated as described above followed by Western blot analysis with an anti-phospho Akt anti-
body. Reprobing of the blot with total Akt antibodies veri¢es equal loading of proteins. A representative blot out of n = 3 individual experi-
ments is shown. C,D: HUVEC were transiently transfected with either empty vector or constitutively active Akt. After transfection, cells were
¢rst incubated for 6 h in EBM containing 1% BSA and then in EBM supplemented with growth factors and 10% FCS. Following 1 h incuba-
tion, TNFK was added at a concentration of 100 ng/ml for 18 h. Data are mean þ S.E.M., *P6 0.01 versus vector, **P6 0.05 versus vec-
tor+TNF, n = 5. Western blot analysis with anti-myc antibody to control for Akt expression is shown in D.
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importance in the protection against replicative senescence.
Moreover, Akt-mediated regulation of telomerase activity
might contribute to the maintenance of the integrity of the
endothelium and, therefore, a¡ect the development of age-
related diseases such as atherosclerosis.
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